Evaluation of fibroblast growth factor 23 as a marker of severity in stable chronic obstructive pulmonary disease
Monaldi Archives for Chest Disease · 2025
DOI: 10.4081/monaldi.2025.3271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Monaldi Archives for Chest Disease, 2025. Verfasst von Simarpreet Singh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary, Critical Care and Sleep Medicine, Government Medical College and Hospital, Chandigarh. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Fibroblast Growth Factors. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: COPD
Abstract (Originalsprache)
Chronic obstructive pulmonary disease (COPD), a multi-component disease, is one of the leading causes of morbidity and mortality globally. Considering the drawbacks of current severity markers of COPD, there is a need to find newer alternatives that are easily accessible and provide insight into the underlying pathophysiology of the disease. This study evaluated fibroblast growth factor 23 (FGF23), a pro-inflammatory hormone, as a severity marker for COPD. A total of 54 stable COPD patients were recruited as per the inclusion and exclusion criteria. All participants were subjected to spirometry and body plethysmography with diffusion capacity of lungs for carbon monoxide (DLCO) evaluation. Plasma FGF23 levels were measured for all participants. This study aimed to evaluate FGF23 as a severity indicator of COPD, along with its association with serum phosphate levels, static lung volumes, and DLCO. The mean age of the study population (n=54) was 59±11 years. The majority of study participants had moderate COPD (50%), followed by severe (27.8%), mild (20.4%), and very severe (1.9%). The mean plasma FGF23 value observed was 115±169 pg/mL. A significant negative correlation was observed between FGF23 levels and forced expiratory volume in 1 second (FEV1) (% predicted), demonstrating the diagnostic role of FGF23. The phosphaturic action of FGF23 was validated by a strong negative correlation observed between serum phosphate and plasma FGF23 levels. Receiver-operating characteristic curve analysis of FGF23 showed that cut-off levels of 73.71 pg/mL can be used to distinguish mild to moderate COPD from severe to very severe, with a sensitivity and specificity of 62.5% and 68.4%, respectively. FGF23 levels were found to be significantly increased in individuals with poor lung function and compromised lung volumes. FGF23 levels were negatively correlated with FEV1 (% predicted) and can be used as a potential severity marker. Hence, plasma FGF23 levels showed a promising role as a severity marker of COPD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary, Critical Care and Sleep Medicine, Government Medical College and Hospital, Chandigarh.
- Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh.
- Department of Biochemistry, Government Medical College and Hospital, Chandigarh.
ORCID-Profile: Simarpreet Singh, Surabhi Jaggi, Seema Gupta, Chahat Bhatia, Varinder Saini
Zitieren
APA
Singh, S., Jaggi, S., Gupta, S., Aggarwal, D., Kaur Sodhi, M., Bhatia, C., & Saini, V. (2025). Evaluation of fibroblast growth factor 23 as a marker of severity in stable chronic obstructive pulmonary disease. Monaldi Archives for Chest Disease. https://doi.org/10.4081/monaldi.2025.3271
Vancouver
Singh S, Jaggi S, Gupta S, Aggarwal D, Kaur Sodhi M, Bhatia C, et al. Evaluation of fibroblast growth factor 23 as a marker of severity in stable chronic obstructive pulmonary disease. Monaldi Archives for Chest Disease. 2025. doi:10.4081/monaldi.2025.3271
BibTeX
@article{Singh2025,
author = {Singh, Simarpreet and Jaggi, Surabhi and Gupta, Seema and Aggarwal, Deepak and Kaur Sodhi, Mandeep and Bhatia, Chahat and Saini, Varinder},
title = {Evaluation of fibroblast growth factor 23 as a marker of severity in stable chronic obstructive pulmonary disease},
journal = {Monaldi Archives for Chest Disease},
year = {2025},
doi = {10.4081/monaldi.2025.3271}
}
EUVIMED